RIPK3—a predictive marker for personalized immunotherapy?
Cancer immunotherapy is an attractive therapeutic option but it is currently unclear which patient may benefit from such approaches. Using the model of cervical cancer, we have demonstrated that PolyIC-driven immunogenicity strictly depends on the necroptosis regulator RIPK3 in the neoplastic cells....
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2016-04-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2015.1075695 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846166470472499200 |
|---|---|
| author | Sigrun Smola |
| author_facet | Sigrun Smola |
| author_sort | Sigrun Smola |
| collection | DOAJ |
| description | Cancer immunotherapy is an attractive therapeutic option but it is currently unclear which patient may benefit from such approaches. Using the model of cervical cancer, we have demonstrated that PolyIC-driven immunogenicity strictly depends on the necroptosis regulator RIPK3 in the neoplastic cells. This proposes RIPK3 as a novel predictive marker for personalization of cancer immunotherapy |
| format | Article |
| id | doaj-art-33e4a3f47fb845a5bcb4e6eef9557ed5 |
| institution | Kabale University |
| issn | 2162-402X |
| language | English |
| publishDate | 2016-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-33e4a3f47fb845a5bcb4e6eef9557ed52024-11-15T15:56:37ZengTaylor & Francis GroupOncoImmunology2162-402X2016-04-015410.1080/2162402X.2015.1075695RIPK3—a predictive marker for personalized immunotherapy?Sigrun Smola0Institute of Virology, Saarland University, Homburg/Saar, GermanyCancer immunotherapy is an attractive therapeutic option but it is currently unclear which patient may benefit from such approaches. Using the model of cervical cancer, we have demonstrated that PolyIC-driven immunogenicity strictly depends on the necroptosis regulator RIPK3 in the neoplastic cells. This proposes RIPK3 as a novel predictive marker for personalization of cancer immunotherapyhttps://www.tandfonline.com/doi/10.1080/2162402X.2015.1075695CancerdsRNADendritic cellsImmune responseRIPK3 |
| spellingShingle | Sigrun Smola RIPK3—a predictive marker for personalized immunotherapy? OncoImmunology Cancer dsRNA Dendritic cells Immune response RIPK3 |
| title | RIPK3—a predictive marker for personalized immunotherapy? |
| title_full | RIPK3—a predictive marker for personalized immunotherapy? |
| title_fullStr | RIPK3—a predictive marker for personalized immunotherapy? |
| title_full_unstemmed | RIPK3—a predictive marker for personalized immunotherapy? |
| title_short | RIPK3—a predictive marker for personalized immunotherapy? |
| title_sort | ripk3 a predictive marker for personalized immunotherapy |
| topic | Cancer dsRNA Dendritic cells Immune response RIPK3 |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2015.1075695 |
| work_keys_str_mv | AT sigrunsmola ripk3apredictivemarkerforpersonalizedimmunotherapy |